198 related articles for article (PubMed ID: 12109805)
1. Combined-modality therapy for rectal cancer using irinotecan.
Minsky BD
Oncology (Williston Park); 2002 May; 16(5 Suppl 5):35-8. PubMed ID: 12109805
[TBL] [Abstract][Full Text] [Related]
2. Combined-modality therapy of rectal cancer with irinotecan-based regimens.
Minsky BD
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):49-55. PubMed ID: 15685836
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan in preoperative combined-modality therapy for locally advanced rectal cancer.
Mitchell EP
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):56-9. PubMed ID: 11200151
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy using CPT-11, leucovorin plus bolus 5-fluorouracil and radiotherapy in patients with rectal cancer. A feasibility study.
Kalofonos HP; Kardamakis D; Bamias A; Skarlos D; Papakostas P; Bafaloukos D; Sakantamis A; Pavlidis N; Fountzilas G
Anticancer Res; 2003; 23(2C):1687-91. PubMed ID: 12820441
[TBL] [Abstract][Full Text] [Related]
5. [Chemotherapy and rectal cancer].
Michel P; Di Fiore F
Cancer Radiother; 2011 Oct; 15(6-7):436-9. PubMed ID: 21885319
[TBL] [Abstract][Full Text] [Related]
6. Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer.
Klautke G; Feyerherd P; Ludwig K; Prall F; Foitzik T; Fietkau R
Br J Cancer; 2005 Apr; 92(7):1215-20. PubMed ID: 15785742
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy of irinotecan, 5-fluorouracil and leucovorin in patients with advanced rectal cancer. Report of two cases.
Hasegawa H; Watanabe M; Baba H; Yoshinare K; Mukai M; Kubota T; Kitajima M
Hepatogastroenterology; 2002; 49(46):891-3. PubMed ID: 12143234
[TBL] [Abstract][Full Text] [Related]
8. Preoperative chemoradiation for locally advanced rectal cancer: emerging treatment strategies.
Crane CH; Janjan NA; Mason K; Milas L
Oncology (Williston Park); 2002 May; 16(5 Suppl 5):39-44. PubMed ID: 12109806
[TBL] [Abstract][Full Text] [Related]
9. Integration of novel agents into combined-modality treatment for rectal cancer patients.
Rödel C; Sauer R
Strahlenther Onkol; 2007 May; 183(5):227-35. PubMed ID: 17497093
[TBL] [Abstract][Full Text] [Related]
10. Combined modality treatment for rectal cancer.
Zhu AX; Willett CG
Semin Oncol; 2005 Feb; 32(1):103-12. PubMed ID: 15726512
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer.
Choi HJ; Kim NK; Keum KC; Cheon SH; Shin SJ; Baik SH; Choen JH; Rha SY; Roh JK; Jeung HC; Chung HC; Ahn JB
Radiother Oncol; 2008 Jun; 87(3):361-6. PubMed ID: 18439695
[TBL] [Abstract][Full Text] [Related]
12. [Pathological changes of rectal cancer after irinotecan, 5-fluorouracil or combined short-term radiotherapy].
Ma JJ; Liang XB; Fan L; Chen MX; Yan D; Li CY; Jiang HY; Hu XZ
Zhonghua Yi Xue Za Zhi; 2011 Aug; 91(29):2042-5. PubMed ID: 22093932
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine, irinotecan, oxaliplatin (CAPIRINOX) and concomitant irradiation in advanced rectal cancer: the Lyon R-02-01 phase I trial.
Heudel P; Romestaing P; Barbet N; Falandry C; You B; Glehen O; Freyer G
Clin Oncol (R Coll Radiol); 2008 Jun; 20(5):369-74. PubMed ID: 18406583
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation.
Díaz-González JA; Calvo FA; Cortés J; García-Sabrido JL; Gómez-Espí M; Del Valle E; Muñoz-Jiménez F; Alvarez E
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1122-8. PubMed ID: 16406393
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114.
Tepper JE; O'Connell M; Niedzwiecki D; Hollis DR; Benson AB; Cummings B; Gunderson LL; Macdonald JS; Martenson JA; Mayer RJ
J Clin Oncol; 2002 Apr; 20(7):1744-50. PubMed ID: 11919230
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.
; Ryan DP; Niedzwiecki D; Hollis D; Mediema BE; Wadler S; Tepper JE; Goldberg RM; Mayer RJ
J Clin Oncol; 2006 Jun; 24(16):2557-62. PubMed ID: 16636336
[TBL] [Abstract][Full Text] [Related]
17. A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer.
Navarro M; Dotor E; Rivera F; Sánchez-Rovira P; Vega-Villegas ME; Cervantes A; García JL; Gallén M; Aranda E
Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):201-5. PubMed ID: 16814947
[TBL] [Abstract][Full Text] [Related]
18. Organ preservation in rectal cancer.
Valentini V; Ziccarelli L; Rosetto ME; Marmiroli L; Coco C
Rays; 1997; 22(3):454-9. PubMed ID: 9446950
[TBL] [Abstract][Full Text] [Related]
19. Combined-modality therapy for rectal cancer: future prospects.
Czito BG; Willett CG; Bendell JC
Clin Colorectal Cancer; 2007 Sep; 6(9):625-33. PubMed ID: 17945034
[TBL] [Abstract][Full Text] [Related]
20. Preoperative irinotecan/5-FU/leucovorin plus concurrent radiotherapy in rectal cancer.
Chitapanarux I; Kamnerdsupaphon P; Lorvidhaya V; Siriwittayakorn P; Tharavichitkul E; Somwangprasert A; Sukthomya V
Gan To Kagaku Ryoho; 2008 Jan; 35(1):77-82. PubMed ID: 18195532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
